{"id":"W4413107688","doi":"10.1136/jitc-2025-011475","title":"First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors","year":2025,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Immunogenicity; CD8; Pharmacokinetics; Pharmacodynamics; Cytotoxic T cell; Agonist; Tolerability; Adverse effect; Pharmacology; Receptor; Antibody; CD28; T cell; Internal medicine; Immune system; Immunology; In vitro; Chemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001720281,0.001595426,0.001669491,0.0003222395,0.0005138693,0.0007972725,0.0004885414,0.0008148693,0.003487661],"category_scores_gemma":[0.0006615224,0.0004744783,0.000971392,0.0002492035,0.0007589626,0.0007536512,0.0003476625,0.002358036,0.0008245317],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001270687,"about_ca_system_score_gemma":0.001667605,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001000802,"about_ca_topic_score_gemma":0.003078664,"domain_scores_codex":[0.9995437,0.0001951727,0.00001700583,0.00007348947,0.00004399151,0.0001265604],"domain_scores_gemma":[0.9994693,0.00008152094,0.0001143371,0.00004197779,0.00004597397,0.0002467791],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5062814,0.1333801,0.03380148,0.001638733,0.002090877,0.001069384,0.001030941,0.005986784,0.1086698,0.0004439095,0.01055946,0.1950472],"study_design_scores_gemma":[0.2184172,0.7266545,0.03484404,0.0000474333,0.00059438,0.0006831238,0.0001528319,0.001352309,0.01077488,0.000229953,0.006212832,0.00003652959],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9933231,0.001274763,0.0003767977,0.0002947928,0.00005608797,0.002270546,0.00102224,0.00006392546,0.001317747],"genre_scores_gemma":[0.99223,0.0008661438,0.001004339,0.0005623617,0.0001009069,0.001734736,0.001485022,0.00002264064,0.001993892],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003487661,"threshold_uncertainty_score":0.01166731,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01138866255083362,"score_gpt":0.3475119262727261,"score_spread":0.3361232637218926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}